ASH News Daily 2013 - Day 3 - (Page B-22)

ASH News Daily Page B-22 Monday, December 9, 2013 ® Clinicians «« From Page B-3 Practice Update ASH condenses all of its practice information in the form of a bi-monthly electronic newsletter called the Practice Update. Sign up to receive the Practice Update by emailing app@hematology.org. The ASH Academy -402712 RCW McCann Healthcare, LLC - the Client: Society's Work 2013 Ad new e-learning Project: platform Campaign: AMGEN The ASH Creative: 77144-R1-V1 Academy is a unified B2 AE: platform that provides the most current practice tools, clinical support, and educational products that he- matologists need for every stage of their career. Clinicians can use the new Practice Improvement Modules (PIMs) to assess, improve, and evaluate their practice's performance in diagnosis and treatment measures for myelodysplastic syndromes and nonHodgkin lymphoma management. Publication: ASH News Daily IO #: None ASH Self-Assessment 2013-12/01 Issue: Program Jr(ASH-SAP) P4C Ad Type: The ASH Academy also allows heB: = None matologists to7"access continuing edT: = x 10" ucation and =knowledge assessment S: None tests based1 on the Society's recently Proofs: launched fifth edition of the ASH Self-Assessment Program (ASH-SAP). The ASH-SAP is a helpful educationT: 7" al resource for clinicians to improve practice methods and stay current with professional education and certification requirements. PQRS Resources - ASH Launches New PQRS Pro Registry Ship Info: ASH News Daily ASH has partnered with NetASH News Daily Health 4341 Montgomery Ave.the ASH PQRS to develop Pro registry, a tool developed to faBethesda, MD 20814 cilitate theTim Mercer Attn: aggregation and submission of T: 301-951-1881 quality measure data to the Medicare Physician Quality ReportE: tmercer@showdailies.com ing System (PQRS). The PQRS Pro registry will empower members to take advantage of the clinical benefit and financial incentive of the 0.5 percent reporting incentive on all 2013 Medicare claims and avoid the 1.5 percent penalty in 2015 for non-participation in 2013. PQRS Pro will validate that your reporting is incentive-eligible and help ensure that you avoid impending payment adjustments. For more information, go to www.hematology.org/PQRSPro. Quick-Reference Pocket Guides ASH publishes pocket‐sized quick reference guides for clinicians. Stop by the ASH Booth (#2501) to pick up copies of the pocket guides on heparin-induced thrombocytopenia (HIT), immune thrombocytopenia (ITP), von Willebrand disease (VWD), red blood cell transfusion, and the Society's most recent guide on thrombocytopenia in pregnancy. (Note: The von Willebrand disease guide was revised in 2012 to include up-to-date information including a bleeding score. ASH's pocket guide on anticoagulation is currently being revised and is not available at this time.) ASH Pocket Guide Mobile Download In addition to printed pocket guides, ASH disseminates this information via mobile downloads for SmartPhones and SmartTablets. Mobile downloads of ASH's pocket guide app on HIT, ITP, VWD are accessible through the Apple Store for use on the iPhone and iPad, and the Android Market for use on all Android devices at no cost. The Blackberry version is available from App World. What is BiTE ? ® T: 10" Consult a Colleague A member service designed to help facilitate the exchange of information between hematologists and their peers, accessible at www. hematology.org/Consult. BiTE® (bispecific T-cell engager) is an innovative area of research that uses a technology designed to help activate the potential of T cells to target malignant cells.1,2 Gibson Memorial Award «« From Page B-7 Amgen is committed to investigating this area of research. Please visit http://www.amgenoncology.com References: 1. Nagorsen D, Baeuerle PA. Exp Cell Res. 2011;317:1255-1260. 2. Baeuerle PA, Kufer P, Bargou R. Curr Opin Mol Ther. 2009;11:22-30. Statements are based on the company's current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen's filings with the US Securities and Exchange Commission. 77144-R1-V1_AMGEN-Blin_ASHNewsDaily_Dec2013_JrP4C.indd 1 © 2013 Amgen Inc. All rights reserved. 77144-R1-V1 10/30/13 12:27 PM Dominant Familial Immune Thrombocytopenia by Genome-Wide Linkage Analysis and Whole Genome Sequencing," will be presented during the Oral Session, "Disorders of Platelet Number or Function: Hereditary Thrombocytopenia and Pathophysiological Insights" this afternoon at 4:30 in Room 260-262 of the Ernest N. Morial Convention Center. She will also present this abstract during tomorrow morning's Special Symposium on the Basic Science of Hemostasis and Thrombosis: 30 Years of Research into the Thrombotic Microangiopathies. This session will be from 7:15 to 9:15 a.m. in Room 265-268.  http://www.hematology.org/PQRSPro http://www.hematology.org/Consult

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3

Table of Contents

ASH News Daily 2013 - Day 3

https://www.nxtbookmedia.com